Intranasal spray is a feasible method to deliver oxytocin into the central nervous system,[62, 63] and this method has been used in clinical trials to investigate the treatment of oxytocin in neurodevelopment disorders, such as autism spectrum disorder.[64, 65] In our study, intranasal oxytocin treatment was sufficient to reduce MPTP‐induced sEPSC increases in SNc DA neurons (Figure 7) and alleviate the striatum TH reduction in two PD mouse models (Figure 2; Figure S3, Supporting Information). This evidence concerns the gene OXT and Parkinson disease.